Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1996
Peer-review started: May 7, 2019
First decision: May 30, 2019
Revised: June 19, 2019
Accepted: July 3, 2019
Article in press: July 3, 2019
Published online: August 6, 2019
The expression profile of serpin peptidase inhibitor clade A member 3 (SERPINA3) in patients with endometrial cancer has rarely been studied. In the present study, we detected the protein levels of SERPINA3 in patients with endometrial cancer and the correlation between the expression of SERPINA3 and the prognosis for endometrial cancer. The result revealed that SERPINA3 expression was significantly up-regulated in endometrial cancer and was closely correlated with pathological grade, clinical stage, vascular invasion, and lymph node metastasis. These findings indicated that SERPINA3 can be used as a prognostic biomarker for endometrial cancer and as one of the targets for bio-targeted therapy for endometrial cancer.
The results of the present study may provide insight into the application of SERPINA3 as a predictor of clinical outcomes and a potential therapeutic target for endometrial cancer.
The present study aimed to assess the significance of SERPINA3 levels in patients with endometrial cancer.
The present study examined tissue samples which were available from patients with endometrial cancer and patients with normal endometrial tissues. Tissue microarrays were constructed and immunohistochemical staining was performed. The expression of SERPINA3 mRNA was detected by quantitative PCR. The data were analyzed with SPSS19.0 software.
We found that SERPINA3 expression was higher in endometrial cancer compared to normal tissues and up-regulated SERPINA3 was closely correlated with pathological grade, clinical stage, vascular invasion, and lymph node metastasis in endometrial cancer.
Assessment of tumor vs normal tissues showed that the expression of SERPINA3 was up-regulated in endometrial cancer. The SERPINA3 protein level in endometrial cancer cells was associated with pathological grade, clinical stage, vascular invasion, and lymph node metastasis, rather than with the age range at which women experienced menopause. SERPINA3 has the potential to be used as a biomarker for prognosis and a specific target for targeted therapy in patients with endometrial carcinomas.
Further studies are warranted to improve our understanding of the role of SERPINA3 in endometrial cancer.